News Releases
- May 20, 2021Annovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
- May 20, 2021Annovis Bio Announces Positive Phase 2 Data: ANVS401 Significantly Lowers Inflammatory Markers in Parkinson's Patients
- May 18, 2021Annovis Bio Appoints Accomplished Neuroscientist Dr. Cheng Fang as VP of Research
- May 13, 2021Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer’s Disease in Persons with Down Syndrome
- May 11, 2021Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
- May 10, 2021Annovis Bio to Ring Closing Bell at the New York Stock Exchange
- May 6, 2021Annovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic Encephalopathy
- April 29, 2021Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome
- April 15, 2021Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman
- March 17, 2021Annovis Bio Presenting at M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
- ,
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - February 2024
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top